BNR revenueFY2025CN¥539.57M
- FY YoY
- +4.6%
- 5Y CAGR
- +4.6%
BNR revenue was CN¥539.57M for fiscal 2025 (ended Dec 31, 2025), up 4.6% from fiscal 2024. Compound annual growth was +4.6% over 5 years. It rose in 5 of the last 7 fiscal years.
Burning Rock Biotech Limited (BNR) financials
For fiscal 2025 (ended Dec 31, 2025), Burning Rock Biotech Limited reported CN¥539.57M of revenue and -CN¥55.35M of net income. Figures are in CNY, the currency of its SEC filings.
- Revenue, FY2025
- CN¥539.57M
- Revenue growth, YoY
- +4.6%
- Net income, FY2025
- -CN¥55.35M
- Net margin
- -10.3%
- Free cash flow, FY2025
- -CN¥33.69M
- Cash
- CN¥478.39M
- Total debt
- CN¥1.70M
FY2018FY2025
FY2018FY2025
FY2018FY2025
BNR revenue and earnings growth
BNR net incomeFY2025-CN¥55.35M
BNR net income was -CN¥55.35M for fiscal 2025 (ended Dec 31, 2025), compared with -CN¥346.63M in fiscal 2024.
BNR free cash flowFY2025-CN¥33.69M
BNR free cash flow was -CN¥33.69M for fiscal 2025 (ended Dec 31, 2025), compared with -CN¥97.68M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥539.57M | CN¥515.82M | CN¥537.43M | CN¥563.24M | CN¥507.86M | CN¥429.90M | CN¥381.68M | CN¥208.87M |
| Cost of revenue | CN¥136.65M | CN¥153.42M | CN¥174.21M | CN¥183.20M | CN¥143.72M | CN¥115.98M | CN¥108.34M | CN¥73.81M |
| Gross profit | CN¥402.91M | CN¥362.40M | CN¥363.23M | CN¥380.04M | CN¥364.15M | CN¥313.92M | CN¥273.33M | CN¥135.06M |
| Research and development | CN¥166.49M | CN¥232.29M | CN¥347.02M | CN¥421.87M | CN¥367.86M | CN¥263.94M | CN¥156.94M | CN¥105.30M |
| Selling, general and admin | CN¥126.09M | CN¥261.64M | CN¥437.82M | CN¥568.28M | CN¥490.26M | CN¥293.80M | CN¥132.16M | CN¥88.30M |
| Operating income | -CN¥54.84M | -CN¥357.56M | -CN¥669.32M | -CN¥980.41M | -CN¥797.06M | -CN¥412.40M | -CN¥169.09M | -CN¥161.40M |
| Interest expense | - | - | - | - | CN¥1.54M | CN¥667.0K | CN¥8.99M | CN¥17.95M |
| Pre-tax income | -CN¥53.79M | -CN¥340.74M | -CN¥651.30M | -CN¥969.25M | -CN¥795.80M | -CN¥407.24M | -CN¥169.16M | -CN¥177.50M |
| Income tax | CN¥1.56M | CN¥5.88M | CN¥2.39M | CN¥1.99M | CN¥899.0K | CN¥0 | CN¥0 | CN¥0 |
| Net income | -CN¥55.35M | -CN¥346.63M | -CN¥653.69M | -CN¥971.23M | -CN¥796.70M | -CN¥407.24M | -CN¥169.16M | -CN¥177.50M |
| EPS, basic | - | - | - | - | CN¥0.00 | CN¥0.00 | -CN¥14.23 | -CN¥10.38 |
| EPS, diluted | - | - | - | - | CN¥0.00 | CN¥0.00 | -CN¥14.23 | -CN¥10.38 |
| Diluted shares | - | - | - | - | 0 | 0 | 23.5M | 22.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | CN¥478.39M | CN¥519.85M | CN¥615.10M | CN¥925.27M | CN¥1.44B | CN¥1.93B | CN¥98.24M | CN¥95.33M |
| Short-term investments | - | - | - | CN¥0 | CN¥63.76M | CN¥362.13M | CN¥313.99M | - |
| Receivables | CN¥169.61M | CN¥152.01M | CN¥126.86M | CN¥109.95M | CN¥92.20M | CN¥88.22M | CN¥88.82M | - |
| Inventory | CN¥48.58M | CN¥53.76M | CN¥69.02M | CN¥130.32M | CN¥123.21M | CN¥68.02M | CN¥58.12M | - |
| Current assets | CN¥738.59M | CN¥776.62M | CN¥884.10M | CN¥1.26B | CN¥1.82B | CN¥2.52B | CN¥706.79M | - |
| Total assets | CN¥820.38M | CN¥885.30M | CN¥1.04B | CN¥1.59B | CN¥2.28B | CN¥2.66B | CN¥847.56M | - |
| Current liabilities | CN¥246.98M | CN¥266.30M | CN¥263.36M | CN¥411.45M | CN¥372.18M | CN¥241.53M | CN¥164.44M | - |
| Short-term debt | - | - | - | CN¥0 | CN¥2.37M | CN¥3.28M | CN¥2.37M | - |
| Long-term debt | CN¥1.70M | CN¥0 | - | - | - | CN¥0 | CN¥18.27M | - |
| Total debt | CN¥1.70M | CN¥0 | - | - | - | CN¥3.28M | CN¥20.64M | - |
| Total liabilities | CN¥285.11M | CN¥304.48M | CN¥271.59M | CN¥429.13M | CN¥433.28M | CN¥242.02M | CN¥212.02M | - |
| Shareholders' equity | CN¥535.26M | CN¥580.83M | CN¥768.41M | CN¥1.16B | CN¥1.85B | CN¥2.42B | -CN¥891.49M | -CN¥603.46M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -CN¥28.44M | -CN¥92.26M | -CN¥255.78M | -CN¥456.81M | -CN¥477.89M | -CN¥73.54M | -CN¥228.04M | -CN¥148.78M |
| Capital expenditures | CN¥5.25M | CN¥5.42M | CN¥8.10M | CN¥62.03M | CN¥204.33M | CN¥60.29M | CN¥42.97M | CN¥23.19M |
| Free cash flow | -CN¥33.69M | -CN¥97.68M | -CN¥263.89M | -CN¥518.84M | -CN¥682.22M | -CN¥133.83M | -CN¥271.01M | -CN¥171.97M |
| Investing cash flow | -CN¥4.39M | -CN¥4.41M | -CN¥9.30M | -CN¥7.46M | CN¥81.70M | -CN¥109.31M | -CN¥346.66M | CN¥106.09M |
| Financing cash flow | CN¥1.90M | -CN¥72.0K | -CN¥48.83M | -CN¥86.24M | -CN¥52.90M | CN¥2.17B | CN¥571.74M | CN¥83.39M |
| Share repurchases | - | - | - | - | CN¥0 | CN¥0 | CN¥3.64M | CN¥0 |
| Stock-based compensation | CN¥13.88M | CN¥155.62M | CN¥260.72M | CN¥326.78M | CN¥282.43M | CN¥173.22M | CN¥22.79M | CN¥5.09M |
| Depreciation and amortization | CN¥21.76M | CN¥52.20M | CN¥133.40M | CN¥124.10M | CN¥47.77M | CN¥33.31M | CN¥31.36M | CN¥24.68M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 4.6% | -4.0% | -4.6% | 10.9% | 18.1% | 12.6% | 82.7% | - |
| Gross margin | 74.7% | 70.3% | 67.6% | 67.5% | 71.7% | 73.0% | 71.6% | 64.7% |
| Operating margin | -10.2% | -69.3% | -124.5% | -174.1% | -156.9% | -95.9% | -44.3% | -77.3% |
| Net margin | -10.3% | -67.2% | -121.6% | -172.4% | -156.9% | -94.7% | -44.3% | -85.0% |
| Free cash flow margin | -6.2% | -18.9% | -49.1% | -92.1% | -134.3% | -31.1% | -71.0% | -82.3% |
| Return on equity | -10.3% | -59.7% | -85.1% | -83.8% | -43.2% | -16.8% | - | - |
| Return on assets | -6.7% | -39.2% | -62.9% | -61.2% | -35.0% | -15.3% | -20.0% | - |
| Current ratio | 2.99 | 2.92 | 3.36 | 3.06 | 4.89 | 10.45 | 4.30 | - |
| Debt to equity | 0.00 | 0.00 | - | - | - | 0.00 | - | - |
Source: XBRL data Burning Rock Biotech Limited files with the SEC, latest filing dated Apr 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
BNR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BNR | CN¥539.57M | +4.6% | -CN¥55.35M | -10.3% | $130.7M |
| UNH | $449.66B | +3.3% | $15.88B | 3.5% | $356.28B |
| ELV | $201.83B | +3.6% | $5.13B | 2.5% | $90.37B |
| CI | $286.32B | +6.8% | $5.99B | 2.1% | $77.89B |
| HUM | $154.19B | +22.0% | $1.25B | 0.8% | $50.82B |
| NTRA | $2.91B | +37.4% | -$164.71M | -5.7% | $46.46B |
| CNC | $203.90B | +9.7% | $1.46B | 0.7% | $33.93B |
| ILMN | $4.54B | +5.8% | $895.00M | 19.7% | $33.38B |
| LH | $14.59B | +6.0% | $1.00B | 6.9% | $30.19B |
BNR FAQ
8 questionsWhat is BNR revenue?
Burning Rock Biotech Limited (BNR) reported CN¥539.57M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 4.6% from the year before.Is BNR profitable?
No. Burning Rock Biotech Limited reported a net loss of CN¥55.35M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does BNR have?
Burning Rock Biotech Limited reported CN¥478.39M in cash and cash equivalents and CN¥1.70M of debt on its most recent balance sheet in SEC filings.How fast is BNR revenue growing?
Burning Rock Biotech Limited's revenue changed +4.6% in fiscal 2025, to CN¥539.57M. Its compound annual growth rate was +4.6% over 5 years.What is BNR gross margin?
Burning Rock Biotech Limited's gross profit was CN¥402.91M on CN¥539.57M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 74.7%.What is BNR free cash flow?
Burning Rock Biotech Limited generated -CN¥33.69M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -CN¥28.44M less capital expenditures.When did BNR last report financial results?
The latest statements here come from Burning Rock Biotech Limited's 20-F filed on Apr 28, 2026, covering the period ended Dec 31, 2025.Where does this BNR financial data come from?
Quantisnow builds these statements from the structured XBRL data Burning Rock Biotech Limited files with the SEC. It is provided for information only and is not investment advice.